Jimenez, Jonas P.
HRN: 23-51-90 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/08/2023
CO-AMOXICLAV 625MG (TAB)
08/08/2023
08/15/2023
PO
625mg
TID
Soft Tissue Injury
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes